https://kstockbriefing.com
![[Disclosure] Samsung Biologics (207940) – Investor Caution Notice on Stock Futures and Options / 2025-05-29](https://kstockbriefing.com/wp-content/uploads/2026/07/포맷변환-삼성바이오로직스.jpg)
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has issued an investor caution notice disclosing that, due to its corporate spin-off decision, the final trading day for stock futures and options (Oct ’25 through Sep ’26 contracts) will be changed to September 26, 2025, and new contract months will not be listed…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion submitted a corrected disclosure regarding its KRW 100.0B buyback program, adding a note that open-market treasury share purchases will be temporarily paused until the bonus issue record date (June 10, 2025) pursuant to financial regulations. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has corrected its bonus issue disclosure, adjusting the number of new common shares to be issued from 8,477,626 to 8,494,384 due to changes in its treasury share holdings. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Allocation…
Read More “[Disclosure] Celltrion (068270) – Decision on Bonus Issue (Correction) / 2025-05-28” »
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary The Korea Exchange (KRX) announced that it plans to implement market adjustments for Celltrion stock futures and options—including base prices, contract multipliers, and strike prices—effective on the ex-rights date (June 9, 2025) following Celltrion’s bonus issue. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has issued an advance notice announcing that it will hold an online Investor Relations (IR) conference for retail shareholders on May 29, 2025, at 4:30 PM KST to present key matters regarding its corporate spin-off (demerger) and conduct a Q&A session. 📊 [Key Disclosure…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion is modifying its stock listing on May 30, 2025, to reflect the cancellation of 589,276 common shares, reducing total issued shares to 222,425,958 shares. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Listing Modification Execution on Scheduled…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has decided on a bonus issue of 0.04 new common share per 1 existing common share, issuing 8,477,626 new shares with a scheduled listing date of July 25, 2025. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of…
Read More “[Disclosure] Celltrion (068270) – Decision on Bonus Issue / 2025-05-26” »
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has disclosed the signing of a pharmaceutical contract manufacturing agreement with an Asian pharmaceutical company valued at approx. KRW 198.5B (USD 144,028,170), representing 4.37% of its FY2024 consolidated revenue. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Monitoring…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has disclosed the signing of a pharmaceutical contract manufacturing agreement with an Asian pharmaceutical company valued at approx. KRW 198.5B (USD 144,028,170), representing 4.37% of its FY2024 consolidated revenue. 📊 [Key Disclosure Details & Financial Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Monitoring…
![[Disclosure] ALTEOGEN (196170) – Additional Listing (Exercise of Stock Options) / 2025-05-23](https://kstockbriefing.com/wp-content/uploads/2026/08/포맷변환알테오젠.jpg)
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary ALTEOGEN will issue and list 146,140 additional common shares following the exercise of stock options by executives and employees. The listing date is set for May 28, 2025. 📊 [Key Disclosure Details & Major Figures Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Additional…